Human Ghrelin Trifluoroacetate
Supplier: BACHEM AMERICAS INC
Small synthetic molecules called growth-hormone secretagogues (GHSs) stimulate the release of growth hormone (GH) from the pituitary through a G protein-coupled receptor (GHS-R). Recently, ghrelin ("ghre" is the Proto-Indo-European root of the word "grow") has been identified as an endogenous ligand for GHS-R. These peptides consist of 28 amino acids with an octanoyl-residue at Ser³, which is essential for expressing activity. Ghrelin stimulates GH release from rat primary culture pituitary cells in a dose-dependent manner and induces an increase in intracellular Ca²⁺ in GHS-R-expressing cells with an EC₅₀ value of 2.5 nM. Human ghrelin is homologous to rat ghrelin apart from two amino acids. The occurrence of ghrelin in both rat and human indicates that GH release from the pituitary may be regulated not only by hypothalamic GHRH, but also by ghrelin. In future, ghrelin might be used in the treatment of aging patients as well as in patients with idiopathic GH deficiency, obesity, osteoporosis or cardiovascular diseases.
Human ghrelin (GHR), the endogenous ligand of the growth hormone secretagogue receptor (GHS-R), potently stimulates GH release. The Ser³ octanoyl ester turned out to be essential for generating this activity. Ghrelin plays an important role in the short-time regulation of appetite and in the long-time regulation of energy balance and glucose homeostasis. A number of studies showed that ghrelin is also involved in the regulation of gastrointestinal, cardiovascular, and immune functions as well as in bone metabolism.
Learn more
About VWR
Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...